Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesGeorge L. Bakris, Patrick Schloemer, Amer Joseph et al.|New England Journal of Medicine|2020Cited by 2.6k
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisRajiv Agarwal, Gerasimos Filippatos, Bertram Pitt et al.|European Heart Journal|2021Cited by 1.2k
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trialBertram Pitt, Faı̈ez Zannad, Lars Køber et al.|European Heart Journal|2013Cited by 573
Clinical Outcome Endpoints in Heart Failure Trials: A European Society of Cardiology Heart Failure Association Consensus DocumentFaı̈ez Zannad, John J.V. McMurray, Ángeles García et al.|European Journal of Heart Failure|2013Cited by 233
Cinaciguat, a Soluble Guanylate Cyclase Activator: Results from the Randomized, Controlled, Phase IIb COMPOSE Programme in Acute Heart Failure SyndromesMihai Gheorghiade, Alexandre Mebazaa, Stephen J. Greene et al.|European Journal of Heart Failure|2012Cited by 123